Apply for Grants
The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Cognition Biomarkers, 2014miRNA Markers of Cognition
Objective/Rationale:
In previous MJFF-funded research, these researchers identified four promising microRNAs (which regulate gene expression) associated with cognitive status. They profiled the miRNAs... -
Cognition Biomarkers, 2013Alpha-synuclein and Cognitive Decline in Parkinson’s Disease
Objective/Rationale:
Variability in the SNCA gene (which encodes alpha-synuclein, the protein that clumps in Parkinson’s disease) is a major risk factor for PD. Using next-generation... -
Cognition Biomarkers, 2013Assessment of Plasma Glucosylceramides and Ceramides as Biomarkers of Cognitive Impairment in Parkinson's Disease
Objective/Rationale:
Metabolism of the lipids glucosylceramide and ceramide is altered in Parkinson’s disease (PD). GBA mutations in this pathway, causing a build-up of glucosylceramide, increase the... -
Cognition Biomarkers, 2013Insulin-like Growth Factor-1 and DAT Imaging as Biomarkers of Early Cognitive Impairment in Parkinson’s Disease
Objective/Rationale:
Evidence supports that the protein insulin-like growth factor-1 (IGF-1) may be involved in cognitive deficits. An earlier study found that low serum IGF-1 levels... -
Cognition Biomarkers, 2013[18F]flubatine: a novel biomarker of cognition in Parkinson's disease
Objective/Rationale:
Mild cognitive impairment and dementia are frequent symptoms of moderate to advanced Parkinson’s disease (PD). Brain positron emission tomography (PET) study findings confirm post... -
Cognition Biomarkers, 2013Validation of Novel and Traditional Quantitative EEG Biomarkers
Objective/Rationale:
Cognitive problems commonly add to the disability of the motor symptoms of Parkinson’s disease (PD), but there are no highly effective treatments for cognitive dysfunction in PD....
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.